vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $257.2M, roughly 1.4× WESBANCO INC). WESBANCO INC runs the higher net margin — 34.5% vs 8.6%, a 25.9% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
LIVN vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $257.2M |
| Net Profit | $30.9M | $88.6M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | — |
| Net Margin | 8.6% | 34.5% |
| Revenue YoY | 12.1% | — |
| Net Profit YoY | -44.7% | 54.4% |
| EPS (diluted) | $0.57 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $360.9M | $265.6M | ||
| Q3 25 | $357.8M | $261.6M | ||
| Q2 25 | $352.5M | $260.7M | ||
| Q1 25 | $316.9M | $193.2M | ||
| Q4 24 | $321.8M | $162.9M | ||
| Q3 24 | $318.1M | $150.8M | ||
| Q2 24 | $318.6M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $30.9M | $91.1M | ||
| Q3 25 | $26.8M | $83.6M | ||
| Q2 25 | $27.2M | $57.4M | ||
| Q1 25 | $-327.3M | $-9.0M | ||
| Q4 24 | $55.9M | $49.6M | ||
| Q3 24 | $33.0M | $37.3M | ||
| Q2 24 | $16.3M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 43.2% | ||
| Q3 25 | 15.1% | 39.5% | ||
| Q2 25 | 15.4% | 27.2% | ||
| Q1 25 | 15.3% | -5.0% | ||
| Q4 24 | 11.5% | 38.0% | ||
| Q3 24 | 11.2% | 29.7% | ||
| Q2 24 | 12.6% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 8.6% | 34.3% | ||
| Q3 25 | 7.5% | 31.9% | ||
| Q2 25 | 7.7% | 22.0% | ||
| Q1 25 | -103.3% | -4.7% | ||
| Q4 24 | 17.4% | 30.5% | ||
| Q3 24 | 10.4% | 24.7% | ||
| Q2 24 | 5.1% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.57 | $0.97 | ||
| Q3 25 | $0.49 | $0.84 | ||
| Q2 25 | $0.50 | $0.57 | ||
| Q1 25 | $-6.01 | $-0.15 | ||
| Q4 24 | $1.04 | $0.72 | ||
| Q3 24 | $0.60 | $0.54 | ||
| Q2 24 | $0.30 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | — |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $4.1B |
| Total Assets | $2.6B | $27.5B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $635.6M | $956.1M | ||
| Q3 25 | $646.1M | $1.0B | ||
| Q2 25 | $593.6M | $1.2B | ||
| Q1 25 | $738.4M | $1.1B | ||
| Q4 24 | $428.9M | $568.1M | ||
| Q3 24 | $346.4M | $620.9M | ||
| Q2 24 | $329.2M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $1.2B | $4.0B | ||
| Q3 25 | $1.2B | $4.1B | ||
| Q2 25 | $1.1B | $3.8B | ||
| Q1 25 | $1.0B | $3.8B | ||
| Q4 24 | $1.3B | $2.8B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $1.2B | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.6B | $27.7B | ||
| Q3 25 | $2.6B | $27.5B | ||
| Q2 25 | $2.5B | $27.6B | ||
| Q1 25 | $2.6B | $27.4B | ||
| Q4 24 | $2.5B | $18.7B | ||
| Q3 24 | $2.5B | $18.5B | ||
| Q2 24 | $2.5B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | — |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $82.4M | $290.4M | ||
| Q3 25 | $85.1M | $116.9M | ||
| Q2 25 | $62.9M | $105.0M | ||
| Q1 25 | $24.0M | $-26.4M | ||
| Q4 24 | $78.7M | $211.0M | ||
| Q3 24 | $51.0M | $60.7M | ||
| Q2 24 | $43.4M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $280.0M | ||
| Q3 25 | $62.2M | $114.9M | ||
| Q2 25 | $47.8M | $98.3M | ||
| Q1 25 | $13.2M | $-30.7M | ||
| Q4 24 | $68.3M | $200.7M | ||
| Q3 24 | $32.8M | $56.9M | ||
| Q2 24 | $31.2M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 105.4% | ||
| Q3 25 | 17.4% | 43.9% | ||
| Q2 25 | 13.6% | 37.7% | ||
| Q1 25 | 4.2% | -15.9% | ||
| Q4 24 | 21.2% | 123.2% | ||
| Q3 24 | 10.3% | 37.7% | ||
| Q2 24 | 9.8% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 3.9% | ||
| Q3 25 | 6.4% | 0.8% | ||
| Q2 25 | 4.3% | 2.6% | ||
| Q1 25 | 3.4% | 2.2% | ||
| Q4 24 | 3.2% | 6.3% | ||
| Q3 24 | 5.7% | 2.5% | ||
| Q2 24 | 3.8% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | 3.19× | ||
| Q3 25 | 3.18× | 1.40× | ||
| Q2 25 | 2.32× | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | 4.25× | ||
| Q3 24 | 1.55× | 1.63× | ||
| Q2 24 | 2.65× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
